Home/Filings/4/0001725160-22-000178
4//SEC Filing

Brownstein Carrie 4

Accession 0001725160-22-000178

CIK 0001725160other

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 6:37 PM ET

Size

10.2 KB

Accession

0001725160-22-000178

Insider Transaction Report

Form 4
Period: 2022-10-03
Brownstein Carrie
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-10-03+300,000300,000 total
    Exercise: $22.21Exp: 2032-10-02Common Stock (300,000 underlying)
  • Award

    Common Stock

    2022-10-03+100,000100,000 total
  • Award

    Stock Option (Right to Buy)

    2022-10-03+100,000100,000 total
    Exercise: $22.21Exp: 2032-10-02Common Stock (100,000 underlying)
Footnotes (3)
  • [F1]Represents restricted stock units ("RSUs") granted by the Issuer under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan") as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years: 25% of the RSUs will vest on each of the first, second, third and fourth anniversaries of the date of grant.
  • [F2]The options were granted by the Issuer under the 2022 Inducement Plan as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.
  • [F3]The options were granted by the Issuer under the 2022 Inducement Plan as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest as to 100% of the shares on the earlier of (a) FDA approval of a Zentalis product or (b) a Change in Control (as defined in the 2022 Inducement Plan).

Issuer

Zentalis Pharmaceuticals, Inc.

CIK 0001725160

Entity typeother

Related Parties

1
  • filerCIK 0001894232

Filing Metadata

Form type
4
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 6:37 PM ET
Size
10.2 KB